NANOVALENT

NanoValent is advancing a new generation of NANO-ADC like Targeted Nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) IP technology. These TNS may provide a vast improvement over current treatment options including chemotherapy, antibody, immunotherapy and ADC based products. Both by repositioning existing therapies such as chemotherapeutics and by truly targeting and optimising the delivery of emerging candidates including biologicals, small molecules and nucleic acid based therapeutics... NanoValent Pharmaceuticals, Inc. (NanoValent/NVP) is a privately-held company with headquarters in Bozeman (MT) collaborating with Children's Hospital Los Angeles (CHLA) as well as other US academic partners to develop NANO-ADC like novel therapeutic options with enhanced target and delivery characteristics. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a..

Also known as: NanoValent Pharmaceuticals, NanoValent Pharmaceuticals Inc.

Primary location: Bozeman United States